Campylobacteriosis Laboratory Testing Lucy Frederick Florida Department of Health Summer Intern Leah Eisenstein, M.P.H. Janet J. Hamilton, M.P.H. 1
2011 Cases Report date= Jan 1, 2011 to June 27, 2011 1,056 reported cases of campylobacteriosis associated with 1,120 attached laboratory results 203 total errors 18% error rate 2
Types & Frequencies of Errors “Test” ≠ “Result Description”: 126/203 ~ 62% “Test” ≠ “Dx Status” : 70/203 ~ 34% “Outbreak Status” ≠ “Sporadic”: 7/203 ~ 3% Probable + No attached lab = “Outbreak Associated” 3
Test ≠ Result Description “Test” should be “Antigen Detection” 4
Indication of Antigen Testing in Multiple Ways “Campy by EIA” Final “Positive by Campylobacter AG” “Detected by EIA” “Presence of Campylobacter Antigen” “Campylobacter Antigen Positive” “Campylobacter Antigen Detected” “Campylobacter Antigen in Stool” “Campylob.Ag” 5
EIA Antigen Lab Examples Antigen=EIA Example 1 Example 2 Example 4 Example 3 6
Culture Lab Examples Culture=Isolation Example 2 Example 1 Example 3 7
Improving “Dx Status” Laboratory tests received typically indicate “Antigen” or “Culture” Culture=Isolation Antigen=EIA 8
“Culture” corresponds with “Isolation of Campylobacter from any clinical specimen” Selection that should be made with a positive “Culture” lab. 9
“Antigen” corresponds with “Positive EIA stool test for Campylobacter sp.” Selection that should be made with a positive test by “Antigen Detection.” 10
Recommend Documents
Development Services in Automotive TESTING LABORATORY Accredited Testing
Laboratory Testing of Intact Laboratory Testing of Intact Rocks k? Why Test
COVID-19 Laboratory Testing: Then and Now DONNA D. CASTELLONE MS MS,
Laboratory equipment for metal testing SARTOROM is exclusive dealer of:
Laboratory Diagnostic Committee Process for Send-Out Testing Laboratory
MTN 020 LC : HIV Testing Case Study and Study Closeout Edward Livant BS, MPH
Non-Invasive Prenatal Testing Barbara Zehnbauer, Ph.D. Acting Director
Independent Testing & Adulterants D. Duncan, PhD 1 & P . Truj illo 2 1
Point of Care Testing: Taking Us Into the Future Barbara M. Goldsmith, Ph.D.,
Point of Care Testing: Taking Us Into the Future Barbara M. Goldsmith, Ph.D.,
4 The challenge for lymphocytes Very few lymphocytes in the body are specific
CART Global Program Team, Global Drug Development, Novartis Pharmaceuticals
Histol Histopathol (1 996) 11 : 267-274 Histology and Histopathology ln
September 16, 2013 SCIENCE SPOTLIGHT No Nove vel l Mech Mechanism anism
1 Dendritic Cells, Antigen Presentation, T Lymphocyte Activation Abul K.
1 Antigen Presenting Cells, Antigen Presentation, T Lymphocyte Activation
Validation of Commercial tool Antibodies The Antibody Society Webcast series
Activating the immune system to fight cancer Presentation June 2020 |
Challenges in the replacement of in-vivo testing for Clostridial vaccines 29
Gastrointestinal Devices for Long-T erm In Situ Delivery of Therapeutic
Unlocking the potential of innovative medicines Photochemical enhancement of
Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II